Neon Therapeutics Inc (NASDAQ:NTGN) was the target of a large growth in short interest during the month of July. As of July 31st, there was short interest totalling 600,600 shares, a growth of 5.4% from the June 30th total of 569,900 shares. Approximately 4.4% of the shares of the company are short sold. Based on an average trading volume of 180,700 shares, the days-to-cover ratio is presently 3.3 days.
NASDAQ NTGN traded up $0.09 on Friday, reaching $2.90. The stock had a trading volume of 115,800 shares, compared to its average volume of 162,820. The company has a debt-to-equity ratio of 0.12, a current ratio of 6.13 and a quick ratio of 6.13. The firm has a fifty day moving average of $3.57 and a two-hundred day moving average of $5.02. Neon Therapeutics has a 1-year low of $2.31 and a 1-year high of $12.69. The company has a market cap of $85.42 million, a P/E ratio of -0.52 and a beta of 1.62.
Neon Therapeutics (NASDAQ:NTGN) last issued its quarterly earnings data on Tuesday, August 6th. The company reported ($0.79) EPS for the quarter, missing analysts’ consensus estimates of ($0.78) by ($0.01). Research analysts predict that Neon Therapeutics will post -2.55 EPS for the current fiscal year.
Large investors have recently added to or reduced their stakes in the company. FMR LLC lifted its position in shares of Neon Therapeutics by 1.1% during the 4th quarter. FMR LLC now owns 2,079,669 shares of the company’s stock valued at $10,461,000 after acquiring an additional 23,075 shares during the period. BlackRock Inc. lifted its position in shares of Neon Therapeutics by 12.0% during the 4th quarter. BlackRock Inc. now owns 307,782 shares of the company’s stock worth $1,548,000 after buying an additional 32,943 shares during the last quarter. Bank of America Corp DE lifted its position in shares of Neon Therapeutics by 42.7% during the 4th quarter. Bank of America Corp DE now owns 21,712 shares of the company’s stock worth $109,000 after buying an additional 6,493 shares during the last quarter. Northern Trust Corp lifted its position in shares of Neon Therapeutics by 68.9% during the 4th quarter. Northern Trust Corp now owns 88,678 shares of the company’s stock worth $446,000 after buying an additional 36,170 shares during the last quarter. Finally, Bank of New York Mellon Corp lifted its position in shares of Neon Therapeutics by 17.6% during the 4th quarter. Bank of New York Mellon Corp now owns 19,427 shares of the company’s stock worth $98,000 after buying an additional 2,905 shares during the last quarter. Hedge funds and other institutional investors own 69.53% of the company’s stock.
About Neon Therapeutics
Neon Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in developing neoantigen-targeted therapies for cancers in the United States. It is developing NEO-PV-01, a neoantigen vaccine that is in Phase Ib clinical trial in combination with nivolumab for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of estrogen-receptor-positive breast cancer.
Featured Story: Death Cross
Receive News & Ratings for Neon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.